Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
Exilby’s German approval gives chronic pain medicine a rare non-opioid test case. Can Vertanical convert data into adoption?
Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.